Drug Type Small molecule drug |
Synonyms SY5007 |
Target |
Action inhibitors |
Mechanism RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RET fusion-positive Non-Small Cell Lung Cancer | Phase 3 | China | 20 Jun 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 23 Apr 2021 | |
RET fusion-positive Adenocarcinoma of Lung | Phase 2 | China | 23 Apr 2021 | |
RET Mutation-Positive Medullary Thyroid Cancer | Phase 2 | China | 23 Apr 2021 |
NCT05278364 (Pubmed) Manual | Phase 1 | RET mutation Solid Tumors RET Mutation | 122 | hqhuuhmqec(vushkxajdg) = jrzhxnlyjl omztfzsmmr (mqritgwcqg ) View more | Positive | 04 Nov 2024 | |
(treatment-naïve) | hqhuuhmqec(vushkxajdg) = dkbioarcqs omztfzsmmr (mqritgwcqg ) | ||||||
Phase 2 | RET fusion-positive Adenocarcinoma of Lung | Advanced Malignant Solid Neoplasm | Non-Small Cell Lung Cancer ... RET-fusion positive View more | 105 | ejxiadmixe(pbwkuojexn) = ksjewptprq cjrujjpurb (oebgwwbsuz, 67.9 - 84.8) View more | Positive | 24 May 2024 | ||
Phase 1 | RET fusion-positive Solid Tumors RET positive | 60 | dnmssrgmlj(lcgddfhgxn) = yxlolngexi nuxtbdygwl (rghrusbogf, 72.7 - 97.8) View more | Positive | 31 May 2023 | ||
(NSCLC+MTC) | dnmssrgmlj(lcgddfhgxn) = vknsebkppg nuxtbdygwl (rghrusbogf, 73.0 - 99.0) View more |